文献速递前列腺癌

前列腺癌检测:尿液生物传感器系统综述

Prostate cancer detection: a systematic review of urinary biosensors.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-01-08

该研究于2021年5月系统检索文献,纳入14篇尿液生物传感器检测前列腺癌的研究,多数报告能较好区分前列腺癌患者与对照。但临床研究仅在小队列患者中进行,尚需大规模试验验证,且能否区分侵袭性与惰性癌尚未解决。

要点

  • 多数尿液生物传感器研究报告了前列腺癌患者与对照之间良好的区分能力。
  • 临床研究仅在小型患者队列中进行,尚需大规模试验验证。
  • 能否区分侵袭性与惰性癌尚未解决,需优化生物标志物组合与长期临床试验。

核心结论

  • 本综述强调尿液生物传感器用于非侵入性前列腺癌检测的潜力,但临床研究迄今仅在小队列患者中进行,尚需大规模试验验证所提出的方法。
  • 综述所纳入概念验证研究的共识是,需要将生物标志物适当组合到多重生物传感器平台中,才能实现准确的诊断检测。
  • 此类设备能否区分侵袭性与惰性癌尚未得到解决,因为这需要优化的生物标志物组合和长期临床试验。

研究设计与样本

  • 系统综述,于2021年5月检索PubMed Medline数据库、Embase和Web of Science。
  • 共识别76条记录,经筛选和合格性评估后纳入14篇文章进行讨论。
  • 目的是审查在来源于前列腺癌患者尿液样本上测试的生物传感器的结构设计与性能。

主要发现

  • 共识别76条记录,经筛选和合格性评估后纳入14篇文章。
  • 所纳入的生物传感器按目标生物标志物和所用检测技术以及临床研究结果进行讨论。
  • 大多数工作报告了前列腺癌患者与对照之间良好的区分能力。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 临床研究迄今仅在小队列患者中进行,尚需大规模试验验证所提出的方法。
  • 此类设备能否区分侵袭性与惰性癌尚未得到解决,因为这需要优化的生物标志物组合和长期临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current diagnostic methods for prostate cancer are invasive and lack specificity towards aggressive forms of the disease, which can lead to overtreatment. A new class of non-invasive alternatives is under development, in which urinary biomarkers are detected using biosensing devices to offer rapid and accurate prostate cancer diagnosis. These different approaches are systematically reviewed and their potential for translation to clinical practice is evaluated. METHODS: A systematic review of the literature was performed in May 2021 using PubMed Medline database, Embase, and Web of Science. The objective was to review the structural designs and performance of biosensors tested on urine samples from patients with prostate cancer. RESULTS: A total of 76 records were identified. After screening and eligibility, 14 articles were included and are discussed in this paper. The biosensors were discussed based on the target biomarkers and detection technologies used, as well as the results of the clinical studies. Most of the works reported good discrimination between patients with prostate cancer and controls. CONCLUSIONS: This review highlights the potential of urinary biosensors for non-invasive prostate cancer detection. However, clinical studies have so far only been conducted on small cohorts of patient, with large scale trials still needed to validate the proposed approaches. Overall, the consensus arising from the proof of concepts studies reviewed here, is that an adequate combination of biomarkers into multiplex biosensor platforms is required to achieve accurate diagnostic tests. Furthermore, whether such devices can discriminate between aggressive and indolent cancer has not yet been addressed, because it entails optimized biomarkers panels and long-term clinical trials.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Chan KM, Gleadle JM, O'Callaghan M, et al. Prostate cancer detection: a systematic review of urinary biosensors. Prostate Cancer Prostatic Dis. 2022. PMID: 34997229. doi:10.1038/s41391-021-00480-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。